Use your antibodies-online credentials, if available.
抗Human ROS1 抗体:
抗Rat (Rattus) ROS1 抗体:
抗Mouse (Murine) ROS1 抗体:
Human Polyclonal ROS1 Primary Antibody for ELISA, WB - ABIN4242203
Shiffman, Ellis, Rowland, Malloy, Luke, Iakoubova, Pullinger, Cassano, Aouizerat, Fenwick, Reitz, Catanese, Leong, Zellner, Sninsky, Topol, Devlin, Kane: Identification of four gene variants associated with myocardial infarction. in American journal of human genetics 2005
ROS1 rearrangement was detected in 1.1% of CCA patients. Although rare, conduct of clinical trials using ROS1 inhibitors in these genetically unique patients is warranted.
For intra-hepatic cholangiocarcinomas (IHCC)patients, ROS1, ALK (显示 ALK 抗体) and c-MET expression levels have prognostic significance on clinical outcomes. Although this finding may require further validation, it has led to proposal of a new stratification or enriched biomarker for future phase III trial of anti-EGFR (显示 EGFR 抗体) therapy in IHCC
Polymorphisms rs1333049 and rs10757278 are associated with SCD (显示 SCD 抗体) in men and rs499818 in the women aged over 50 years.
Overcome crizotinib resistance in a ROS1-rearranged cancer.
The ROS1 S1986Y/F and ALK C1156Y mutations are homologous and displayed similar sensitivity patterns to ALK/ROS1 TKIs.
Given the results from the ROS1 cohort of the clinical trial PROFILE 1001, crizotinib represents a new treatment option and the first approved therapy for patients with metastatic non-small cell lung cancer whose tumors are ROS1 positive. Crizotinib demonstrated efficacy irrespective of prior treatment status.
ROS1 rearrangements rarely overlap with alterations in EGFR (显示 EGFR 抗体), KRAS, ALK (显示 ALK 抗体), or other targetable oncogenes in NSCLC.
Durable benefits with pemetrexed-based therapies in RET (显示 RET 抗体)-rearranged lung cancers are comparable with ALK (显示 ALK 抗体)- and ROS1-rearranged lung cancers. When selecting therapies for patients with RET (显示 RET 抗体)-rearranged lung cancers, pemetrexed-containing regimens should be considered.
C-ROS-1 is involved in Bone marrow-derived mesenchymal stem/stromal cell fate switching between osteogenesis and adipogenesis, mediated via PI3K (显示 PIK3CA 抗体)/AKT (显示 AKT1 抗体)/mTORC1 signalling.
Findings highlight ROS1 as a candidate biomarker and therapeutic target for oral squamous cell carcinoma.
GPX1-dependent alterations in oxido-reductive stress promote ROS1 activation and mediate vascular remodeling.
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
c-ros and its ligand may be necessary for differentiation of epithelia I and II in mouse.
This proto-oncogene, highly-expressed in a variety of tumor cell lines, belongs to the sevenless subfamily of tyrosine kinase insulin receptor genes. The protein encoded by this gene is a type I integral membrane protein with tyrosine kinase activity. The protein may function as a growth or differentiation factor receptor.
c-Ros receptor tyrosine kinase
, proto-oncogene c-Ros
, proto-oncogene c-Ros-1
, proto-oncogene tyrosine-protein kinase ROS
, receptor tyrosine kinase c-ros oncogene 1
, transmembrane tyrosine-specific protein kinase
, v-ros UR2 sarcoma virus oncogene homolog 1
, v-ros avian UR2 sarcoma virus oncogene homolog 1
, Ros1 proto-oncogene
, heart - derived c - ros - 1 proto - oncogene
, proto-oncogene c-ros